Analysis of Clinical Features and Prognostic Influence Factors in DLBCL Patients With Double Expression of MYC Protein and BCL-2 Protein
Objective To analyze the clinical features and prognostic influence factors on cellular myelocytomatosis viral oncogene(MYC)protein and B cell lymphoma/lewkmia-2(BCL-2)protein double express diffuse large B-cell B-cell lymphoma(DLBCL).Methods A total of 82 DLBCL patients admitted to the Affiliated Suzhou Hospital of Nanjing Medical University from January 2020 to January 2021 were selected,and the expression of MYC protein and BCL-2 protein were detected by immunohistochemistry,and the survival time was analyzed for 3 years,the influencing factors of prognosis were analyzed.Results The improved Ann-Arbor stage Ⅲ to Ⅳ stage,tumor mass diameter≥5 cm and international prognostic index score(IPS)3-4 scores and the proportion of bone marrow invasion of DLBCL patients in the MYC/BCL-2 double-protein expression group were higher than those in the non-MYC/BCL-2 double-protein expression group,the differences were statistically significant(P<0.05).The mean survival time for patients with DLBCL in the MYC/BCL-2 double-protein expression group was(22.35±2.48)months,while the mean survival time for patients in the non-MYC/BCL-2 double-protein expression group was(30.70±1.66)months,the mean survival time of patients with DLBCL in the MYC/BCL-2 double-protein expression group was shorter than that in the non-MYC/BCL-2 double-protein expression group,the differences were statistically significant(P<0.001).The logistic regression analysis showed that modified Ann-Arbor stage(stage Ⅲ to Ⅳ),bone marrow invasion,and double expression of MYC/BCL-2 protein were the risk factors affecting the prognosis of DLBCL patients(P<0.05).Conclusion The clinical characteristics of patients with BLBCL include late stage,tumor mass,more prone to bone marrow invasion and poor prognosis;and double expression of MYC protein and BCL-2 protein can be used as the prognosis factor of DLBCL patients.The article reflects the clinical reference or implementation criteria of the"Chinese Guidelines for Diagnosis and Treatment of Diffuse large B-cell Lymphoma(2013 edition)".
diffuse large B-cell lymphomaMYC proteinBCL-2 proteindouble expressionprognosisinfluence factors
万方数据
维普
